Example 4

Multifactorial optimization of the refolding of Interleukin-4 derivative employing the TRIS-sulfuric acid based system

An attractive combination of aggregation suppressors is the TRIS-base/H_2SO_4-system. Therefore, this system was chosen for further optimization employing a multifactorial analysis.

The total final volume of the refolding solution was 50 mL (glass vials, Schott, Germany). The glass vials were capped with parafilm. Refolding was allowed to run to completion within 24-36 hours with stirring on a magnetic bar stirrer (100-200 rpm). At intervals, samples were withdrawn and analyzed by RP-HPLC (see Example 1).

The protein solution from Example 2, containing denatured, sulfitolyzed protein, is diluted into refolding buffer to give a final protein concentration indicated in Table 3. The following aspects of refolding buffer composition were investigated: concentration of TRIS-base (0.5 to 3 [M]), H_2SO_4 (depending on TRIS-concentration; 0.4 to 1.4 [M]), residual guanidinium hydrochloride concentration (80-400 mM), L-cysteine concentration (0.4 to 4 [mM]), and initial protein concentration (50 to 1000 [mg/L]). The pH of the refolding buffer was adjusted to 7.5. All refolding mixtures contained 1 mM EDTA.

The experiments described in this example was designed to allow multifactorial statistical analysis of correctly folded Interleukin-4 derivative yield data in order to assess the importance of all single factors and all two-factor interactions. A partial cubic experimental design was generated and the resulting data were also analyzed employing a partial cubic model. The coefficients of the polynoms of the partial cubic model are given in Table 2.

Term	TRIS	CYS	Protein	Term	
0	0	0	0	CONSTANT	
1	1	0	0	TRIS-H2SO4_[M]	Linear terms
2	0	1	0	Cysteine_[mM]	
3	0	0	1	Protein_[mg/L]	
4	1	1	0	TRIS-H2SO4_[M]*Cysteine_[mM]	
5	1	0	1	TRIS-H2SO4_[M]*Protein_[mg/L]	Interaction terms
6	0	1	1	Cysteine_[mM]*Protein_[mg/L]	
7	2	0	0	TRIS-H2SO4_[M]^2	
8	0	2	0	Cysteine_[mM]^2	Quadratic terms
9	0	0	2	Protein_[mg/L]^2	
10	1	2	0	TRIS-H2SO4_[M]*Cysteine_[mM]^2	
11	2	1	0	TRIS-H2SO4_[M]^2*Cysteine_[mM]	
12	1	0	2	TRIS-H2SO4_[M]*Protein_[mg/L]^2	Partialcubic terms
13	2	0	1	TRIS-H2SO4_[M]^2*Protein_[mg/L]	
14	0	1	2	Cysteine_[mM]*Protein_[mg/L]^2	
15	0	2	1	Cysteine_[mM]^2*Protein_[mg/L]	

Table 2 Partial cubic model employed for the experimental design of the refolding optimization of Interleukin-4 R121D Y124D

Trial #	TRIS-base	Cysteine	Protein	Ref. Yield	Protein recovery	Overall refolding yield	Purity
				[mg/L]	[%]	[%]	[%]
1	3	4	50	9	81.3	18.00	22.1
2	3	0.4	1000	2.92	10.65	0.29	2.7
3	0.5	4	525	90.45	48.55	17.23	35.5
4	0.5	2.2	1000	137.7	46.34	13.77	29.7
5	1.75	4	1000	199.72	54.77	19.97	36.5
6	1.75	0.4	1000	25.05	27.23	2.50	9.2
7	3	2.2	50	11.3	60.79	22.60	37.2

Trial #	TRIS-base	Cysteine	Protein	Ref. Yield	Protein recovery	Overall refolding yield	Purity
8	0.5	4	50	10.37	53.54	20.73	38.7
9	3	0.4	525	68.32	55.36	13.01	23.5
10	0.5	0.4	525	81.82	36.66	15.58	42.5
11	1.75	0.4	50	13.6	62.08	27.21	43.8
12	0.5	0.4	1000	15.8	18.89	1.58	8.4
13	3	4	1000	176.31	43.94	17.63	40.1
14	1.75	4	525	131.19	68.94	24.99	36.2
15	1.3333	1.6	366.667	93.63	68.21	25.54	37.4
16	2.1667	1.6	366.667	91.95	69.77	25.08	35.9
17	3	2.8	683.333	134.38	55.72	19.67	35.3
18	0.5	1.6	683.333	110.68	48.94	16.20	33.1
20	2.1667	2.8	50	12.49	71.59	24.98	34.9
1	3	4	50	9.38	52.32	18.76	35.9
2	3	0.4	1000	8.94	18.32	0.89	4.9
3	0.5	4	525	97.16	50.43	18.51	36.7
4	0.5	2.2	1000	140.29	45.63	14.03	30.7
5	1.75	4	1000	197.53	56.85	19.75	34.7
6	1.75	0.4	1000	19.75	27.61	1.97	7.2
7	3	2.2	50	15.08	72.5	30.15	41.6

Table 3 Effect of solution conditions (TRIS-H_2SO_4-system) on Interleukin-4 R121D Y124D refolding yield, recovery of soluble protein, overall refolding yield and purity

The yields obtained with selected combinations of these components are shown in Table 3. Inspection of these results shows that, under the experimental conditions employed, the following trends were apparent: (1) best refolding yields are obtained at high protein concentrations (750-1000 [mg/L]); (2) best overall refolding yields are obtained at 250 to 650 [mg/L] total protein concentration; (3) the optimal L-cysteine concentration range is 2.5 to 4 [mM]; (4) the optimal Tris-H_2SO_4-

concentration range is 1.4 to 2.4 [M]; (5) best protein recovery is obtained at low protein concentrations (50 to 250 [mg/L]), high Tris-H_2SO_4-concentrations (2-3 [M]) and 2 to 3.5 [mM] L-cysteine; (6) best purity is obtained at high protein concentrations (400-1000 [mg/L]), high L-cysteine concentrations (2.5-4 [mM]). The purity is indepening on the Tris-H_2SO_4 concentration.

A compromise between optimal refolding yield, purity and protein recovery was identified employing the following settings: 500 mg/L total protein, 3.3 mM L-cysteine, 2 M Tris-H_2SO_4 and 1 mM EDTA.

Checkpoints employing these optimal conditions revealed that the predicted and measured response values fit reasonably well, indicating that the model is adequate.

Overall refolding yield	Predicted:	24.9 [%] (±1.84 StdErr)
	Measured:	25.4 [%] (±0.37 StdErr)
Protein recovery	Predicted:	65.9 [%] (±6.55 StdErr)
	Measured:	62.9 [%] (±0.63 StdErr)
Purity	Predicted:	38.6 [%] (±3.63 StdErr)
	Measured:	40.4 [%] (±0.45 StdErr)
Refolding yield	Predicted:	127 [mg/L] (±14.5 StdErr)
	Measured:	126.9 [mg/L] (±1.85 StdErr)

Example 5

Multifactorial optimization of the refolding of Interleukin-4 derivative employing the Triethanolamine-sulfuric acid based system

Another attractive combination of aggregation suppressors is the Triethanolamine (TEA) /H_2SO_4-system. Therefore, this system was chosen for further optimization and scale-up of the protein concentration.

The total final volume of the refolding solution was 50 mL (glass vials, Schott, Germany). The glass vials were capped with parafilm. Refolding was allowed to run to completion within 24-36 hours with stirring on a magnetic bar stirrer (100-200 rpm). At intervals, samples were withdrawn and analyzed by RP-HPLC (see Example 1).

The protein solution from Example 2, containing denatured, sulfitolyzed protein, is diluted into refolding buffer to give a final protein concentration indicated in Table 5. The following aspects of refolding buffer composition were investigated: concentration of TEA (1 to 2 [M]), H_2SO_4 (depending on TEA-concentration), residual guanidinium hydrochloride concentration (80-400 mM), L-cysteine concentration (0.4 to 10 [mM]), and initial protein concentration (50 to 1000 [mg/L]). The pH of the refolding buffer was adjusted to 7.5. All refolding mixtures contained 1 mM EDTA.

The experiments described in this example was designed to allow multifactorial statistical analysis of correctly folded Interleukin-4 derivative yield data in order to assess the importance of all single factors and all two-factor interactions. A partial cubic experimental design was generated and the resulting data were also analyzed employing a partial cubic model. The coefficients of the polynoms of the partial cubic model are given in Table 4.

Term	TEA	CYS	Protein	Term	
0	0	0	0	CONSTANT	
1	1	0	0	TEA-H2SO4_[M]	Linear terms
2	0	1	0	Cysteine_[mM]	
3	0	0	1	Protein_[mg/L]	
4	1	1	0	TEA-H2SO4_[M]*Cysteine_[mM]	Interaction terms
5	1	0	1	TEA-H2SO4_[M]*Protein_[mg/L]	
6	0	1	1	Cysteine_[mM]*Protein_[mg/L]	
7	2	0	0	TEA-H2SO4_[M]^2	Quadratic terms
8	0	2	0	Cysteine_[mM]^2	
9	0	0	2	Protein_[mg/L]^2	
10	1	2	0	TEA-H2SO4_[M]*Cysteine_[mM]^2	Partial cubic terms
11	2	1	0	TEA-H2SO4_[M]^2*Cysteine_[mM]	
12	1	0	2	TEA-H2SO4_[M]*Protein_[mg/L]^2	
13	2	0	1	TEA-H2SO4_[M]^2*Protein_[mg/L]	
14	0	1	2	Cysteine_[mM]*Protein_[mg/L]^2	
15	0	2	1	Cysteine_[mM]^2*Protein_[mg/L]	

Table 4 Partial cubic model employed for the experimental design of the refolding optimization of Interleukin-4 R121D Y124D

Trial #	TEA	Cysteine	Protein	Ref. Yield	Protein recovery	Overall refolding yield	Purity
[-]	[M]	[mM]	[mg/L]	[mg/L]	[%]	[%]	[%]
1	2	10	0.1	5.91	138.09	5.9	4.3
2	2	0.4	1	135.12	49.49	13.5	27.3
3	0.5	10	0.55	15.23	16.92	2.8	16.4
4	0.5	5.2	1	70.06	19.28	7	36.3
5	1.25	10	1	49.37	18.06	4.9	27.3
6	0.5	5.2	0.1	9.64	66.78	9.6	14.4
7	1.25	0.4	1	167.96	42.5	16.8	39.5
8	2	5.2	0.1	13.66	103.17	13.7	13.2
9	0.5	10	0.1	3.56	76.7	3.6	4.6

Trial #	TEA	Cysteine	Protein	Ref. Yield	Protein recovery	Overall refolding yield	Purity
10	2	0.4	0.55	45.39	54.66	8.3	15.1
11	0.5	0.4	0.55	68.41	31.3	12.4	39.7
12	1.25	0.4	0.1	30.09	77.34	30.1	38.9
13	0.5	0.4	1	90.11	21.55	9	41.8
14	2	10	1	63.75	22.94	6.4	27.8
15	0.5	0.4	0.1	24.18	59.26	24.2	40.8
16	1.25	10	0.55	43.47	31.42	7.9	25.2
17	1	3.6	0.4	107.54	61.7	26.9	43.6
18	1.5	3.6	0.4	118.95	70.26	29.7	42.3
19	2	6.8	0.7	115.96	45.83	16.6	36.1
20	0.5	3.6	0.7	97.81	32.69	14	42.7
21	1.5	6.8	0.1	12.29	75.29	12.3	16.3
1	2	10	0.1	6.51	91.62	6.5	7.1
2	2	0.4	1	136.71	44.08	13.7	31.0
3	0.5	10	0.55	17.13	13.98	3.1	22.3
4	0.5	5.2	1	68.29	17.34	6.8	39.4
5	1.25	10	1	53.25	16.96	5.3	31.4
6	0.5	5.2	0.1	10.75	44.69	10.8	24.1
7	1.25	0.4	1	170.11	39.82	17	42.7
8	2	5.2	0.1	18.01	81.64	18	22.1
9	0.5	10	0.1	4.92	43.65	4.9	11.3

Table 5 Effect of solution conditions (TEA-H_2SO_4-system) on Interleukin-4 R121D Y124D refolding yield, recovery of soluble protein, overall refolding yield and purity

The yields obtained with selected combination of these components are shown in Table 5. Inspection of these results shows that, under the experimental conditions employed, the following trends were apparent: (1) best refolding yields are obtained at high protein concentrations (750-1000 [mg/L]); (2) best overall refolding yields are obtained at 100 to 550 [mg/L] total protein concentration; (3) the optimal L-

cysteine concentration range is 0.4 to 4 [mM]; (4) the optimal TEA-H_2SO_4-concentration range is 1 to 1.6 [M]; (5) best protein recovery is obtained at low protein concentrations (50 to 250 [mg/L]), high TEA-H_2SO_4-concentrations (1.5-2 [M]) and 4 to 10 [mM] L-cysteine; (6) best purity is obtained at high protein concentrations (600-1000 [mg/L]), L-cysteine concentrations ranging between 0.4 and 4 [mM]) and at the TEA-H_2SO_4 concentrations ranging between 0.8 and 1.5 [M]. A compromise between optimal refolding yield, purity and protein recovery was identified employing the following settings: 500 mg/L total protein, 0.8 mM L-cysteine, 1.4 M TEA-H_2SO_4 and 1 mM EDTA.

Checkpoints employing these optimal conditions revealed that the predicted and measured response values fit reasonably well, indicating that the model is adequate.

Overall refolding yield	Predicted:	24.6 [%] (±4.1 StdErr)
	Measured:	24.3 [%] (±0.8 StdErr)
Protein recovery	Predicted:	52.8 [%] (±10.5 StdErr)
	Measured:	58.2 [%] (±4.5 StdErr)
Purity	Predicted:	43.2 [%] (±5.3 StdErr)
	Measured:	41.8 [%] (±3.9 StdErr)
Refolding yield	Predicted:	106.8 [mg/L] (±16.9 StdErr)
	Measured:	121.6 [mg/L] (±2.0 StdErr)

Example 6

Refolding of bovine pancreatic trypsin inhibitor (BPTI, aprotinin) employing the TRIS-sulfuric acid based system

In order to demonstrate that the TRIS/H_2SO_4-system can also be employed for the refolding of other proteins than Interleukin-4 derivatives, the TRIS/H_2SO_4-system was also optimized for BPTI.

The total final volume of the refolding solution was 50 mL (glass vials, Schott, Germany). The glass vials were capped with parafilm. Refolding was allowed to run to completion within 24-36 hours with stirring on a magnetic bar stirrer (100-200 rpm). At intervals, samples were withdrawn and analyzed by RP-HPLC (see Example 1).

The protein solution from Example 2, containing denatured, sulfitolyzed protein, is diluted into refolding buffer to give a final protein concentration indicated in Table 7. The following aspects of refolding buffer composition were investigated: concentration of TRIS (0 to 2 [M]), H_2SO_4 (depending on the concentration of TRIS-base), residual guanidinium hydrochloride concentration (80-400 mM), L-cysteine concentration (0.1 to 4 [mM]), and initial protein concentration (50 to 1000 [mg/L]). The pH of the refolding buffer was adjusted to 7.5. All refolding mixtures contained 1 mM EDTA.

The experiments described in this example was designed to allow multifactorial statistical analysis of correctly folded BPTI yield data in order to assess the importance of all single factors and all two-factor interactions. A partial cubic experimental design was generated and the resulting data were also analyzed employing a partial cubic model. The coefficients of the polynoms of the partial cubic model are given in Table 6.

Term	TRIS	CYS	Protein	Term	
0	0	0	0	CONSTANT	
1	1	0	0	TRIS-H2SO4_[M]	Linear terms
2	0	1	0	Cysteine_[mM]	
3	0	0	1	Protein_[mg/L]	
4	1	1	0	TRIS-H2SO4_[M]*Cysteine_[mM]	Interaction terms
5	1	0	1	TRIS-H2SO4_[M]*Protein_[mg/L]	
6	0	1	1	Cysteine_[mM]*Protein_[mg/L]	
7	2	0	0	TRIS-H2SO4_[M]^2	Quadratic terms
8	0	2	0	Cysteine_[mM]^2	
9	0	0	2	Protein_[mg/L]^2	
10	1	2	0	TRIS-H2SO4_[M]*Cysteine_[mM]^2	Partial cubic terms
11	2	1	0	TRIS-H2SO4_[M]^2*Cysteine_[mM]	
12	1	0	2	TRIS-H2SO4_[M]*Protein_[mg/L]^2	
13	2	0	1	TRIS-H2SO4_[M]^2*Protein_[mg/L]	
14	0	1	2	Cysteine_[mM]*Protein_[mg/L]^2	
15	0	2	1	Cysteine_[mM]^2*Protein_[mg/L]	

Table 6 Partial cubic model employed for the experimental design of the refolding optimization of BPTI

Trial #	TRIS-base	Cysteine	Protein	Ref. Yield	Protein recovery	Overall refolding yield	Purity
[-]	[M]	[mM]	[mg/L]	[mg/L]	[%]	[%]	[%]
1	2	4	50	20.43	85.69	40.86	47.7
2	2	0.1	1000	0	0	0	0
3	0	4	525	159.29	61.05	30.34095	49.7
4	0	2.05	1000	275.45	70.84	27.545	38.9
5	1	4	1000	256.9	71.75	25.69	35.8
6	0	2.05	50	35.67	136.48	71.34	52.3
7	1	0.1	1000	0	2.59	0	0
8	2	2.05	50	19.45	80.85	38.9	48.1
9	0	4	50	8.51	39.92	17.02	42.6
10	2	0.1	525	0	0	0	0
11	0	0.1	525	0	0.4	0	0
12	1	0.1	50	15.71	69.04	31.42	45.5

Trial #	TRIS-base	Cysteine	Protein	Ref. Yield	Protein recovery	Overall refolding yield	Purity
13	0	0.1	1000	0	1.05	0	0
14	2	4	1000	158.93	36.23	15.893	43.9
15	0	0.1	50	5.03	14.13	10.06	71.2
16	1	4	525	18.64	89.48	3.550476	4
17	0.6667	1.4	366.667	107.29	83.34	29.26088	35.1
18	1.3333	1.4	366.667	104.5	82.6	28.49997	34.5
19	2	2.7	683.333	97.4	41.66	14.25367	34.2
20	0	1.4	683.333	149.44	51.46	21.86928	42.5
21	1.3333	2.7	50	14.08	76.21	28.16	36.9
1	2	4	50	16.15	69.37	32.3	46.5
2	2	0.1	1000	1.47	3.44	0.147	4.3
3	0	4	525	162.49	58.91	30.95048	52.5
4	0	2.05	1000	273.77	68.91	27.377	39.7
5	1	4	1000	265.9	78.2	26.59	34
6	0	2.05	50	9.73	39.56	19.46	49.2
7	1	0.1	1000	0	0.94	0	0
8	2	2.05	50	19.18	77.88	38.36	49.3

Table 7 Effect of solution conditions on BPTI refolding yield, recovery of soluble protein and overall refolding yield

The yields obtained with selected combination of these components are shown in Table 7. Inspection of these results shows that, under the experimental conditions employed, the following trends were apparent: (1) best refolding yields are obtained at high protein concentrations (750-1000 [mg/L]); (2) best overall refolding yields are obtained at 500 to 1000 [mg/L] total protein concentration; (3) the optimal L-cysteine concentration range is 2.5 to 4 [mM]; (4) the optimal TRIS-H_2SO_4-concentration range is 0.2 to 1.0 [M]; (5) best protein recovery is obtained at low protein concentrations (50 to 100 [mg/L]), moderate TRIS-H_2SO_4-concentrations

(0.9-1.4[M]) and 1.8 to 3.3 [mM] L-cysteine; (6) best purity is obtained at low protein concentrations (50-100 [mg/L]), L-cysteine concentrations ranging between 0.1 and 0.4 [mM]) and at the TRIS-H_2SO_4 concentrations ranging between 0.1 and 0.5 [M].

A compromise between optimal refolding yield, purity and protein recovery was identified employing the following settings: 700 mg/L total protein, 3.3 mM L-cysteine, 0.3 M TRIS-H_2SO_4 and 1 mM EDTA.

Claims

1. A method for renaturation of proteins comprising adding to a solution of denatured, chemically modified or reduced proteins a refolding buffer containing a primary, secondary or tertiary amine.

2. The method of claim 1 characterised in that the amine has the formula



wherein R_1 and R_2 can be any combination of the ligands H, O=C-NH_2, $(CH_2)_4$-NH_2, $(CH_2)_3$-COOH, $(CH_2)_2$-CHOH-CH_3, CH_2-CH_2-OH, CH_2-CH_3, CH_3, NH_2

and R_3 can be C(NH_2)=NH, C($CH_2OH)_3$, CH_2-CH_2-OH or H

3. The method of any one of claims 1 or 2 wherein the buffer further contains a solubility enhancer.

4. The method of claims 3 wherein solubility enhancer is an ion.

5. The method of claims 3 wherein solubility enhancer is chloride or sulfate.

6. The method of claims 1 to 5 wherein the protein is an interleukin

7. The method of claims 1 to 5 wherein the protein is interleukin 4

8. The method of claims 1 to 5 wherein the protein is a mutein of interleukin 4.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/12607

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/54 C07K14/81 C07K1/113

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 01 87925 A (COX GEORGE N ;BOLDER BIOTECHNOLOGY INC (US); DOHERTY DANIEL H (US)) 22 November 2001 (2001-11-22) * claims 1,17,22,24,27; examples 1-3,5,8,12,14,19,22,23 *	1-8
X	WO 89 01046 A (SCHERING BIOTECH CORP) 9 February 1989 (1989-02-09) example 2	1-8

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

'A' document defining the general state of the art which is not considered to be of particular relevance

'E' earlier document but published on or after the international filing date

'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

'O' document referring to an oral disclosure, use, exhibition or other means

'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
7 March 2003	20/03/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Fausti, S

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	CREIGHTON T.E. ET AL.: "On the biosynthesis of Bovine Pancreatic Trypsin Inhibitor (BPTI): Structure, Processing, Folding, and Disulphide bond formation of the Precursor in Vitro and in Microsomes" J. MOL. BIOL., vol. 232, 1993, pages 1176-1196, XP001058004 * page 1180, left-hand column, 2nd paragraph *	1,3-5
X	WO 96 40784 A (HALLENBECK ROBERT F ;ARVE BO H (US); BILD GARY S (US); CHEN BAO LU) 19 December 1996 (1996-12-19) * abstract; page 9, line 18; examples 1,9,10 *	1-5
X	US 5 453 363 A (RUDOLPH RAINER ET AL) 26 September 1995 (1995-09-26) cited in the application * examples 1c,1d,3-5,6.7,6.8,7,8.6,8.7 *	1-5
X	WO 99 33988 A (CHONG KUN DANG CORP ;KIM CHANG KYU (KR); KIM YONG IN (KR); OH SUNG) 8 July 1999 (1999-07-08) * page 7, lines 15-30; examples 8-12 *	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/12607

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0187925 A	22-11-2001	AU 7485301 A	26-11-2001
		EP 1284987 A2	26-02-2003
		WO 0187925 A2	22-11-2001
WO 8901046 A	09-02-1989	AU 2257488 A	01-03-1989
		EP 0301835 A1	01-02-1989
		WO 8901046 A1	09-02-1989
		ZA 8805540 A	26-04-1989
WO 9640784 A	19-12-1996	AU 713338 B2	02-12-1999
		AU 6477096 A	30-12-1996
		CA 2223745 A1	19-12-1996
		EP 0837883 A2	29-04-1998
		JP 11514334 T	07-12-1999
		WO 9640784 A2	19-12-1996
		US 6319896 B1	20-11-2001
		US 5888968 A	30-03-1999
		US 6323326 B1	27-11-2001
		US 2002137884 A1	26-09-2002
US 5453363 A	26-09-1995	DE 3537708 A1	23-04-1987
		US 5593865 A	14-01-1997
		AT 98648 T	15-01-1994
		AT 131489 T	15-12-1995
		AU 607083 B2	21-02-1991
		AU 4132189 A	04-01-1990
		AU 590029 B2	26-10-1989
		AU 6599386 A	19-05-1987
		CA 1329157 A1	03-05-1994
		CZ 8607526 A3	17-01-1996
		DE 3650449 D1	25-01-1996
		DE 3689404 D1	27-01-1994
		DK 320387 A	23-06-1987
		DK 200001897 A	18-12-2000
		WO 8702673 A2	07-05-1987
		EP 0219874 A2	29-04-1987
		EP 0253823 A1	27-01-1988
		EP 0393725 A1	24-10-1990
		ES 2061434 T3	16-12-1994
		ES 2020498 T3	01-04-1996
		FI 872753 A ,B,	22-06-1987
		FI 933868 A ,B,	03-09-1993
		GR 92300062 T1	31-08-1992
		GR 3018410 T3	31-03-1996
		HK 153496 A	16-08-1996
		HK 153596 A	16-08-1996
		HR 921075 A1	30-06-1995
		HU 204855 B	28-02-1992
		HU 43643 A2	30-11-1987
		IE 62634 B1	22-02-1995
		IL 80325 A	21-06-1992
		JP 2117325 C	06-12-1996
		JP 4218387 A	07-08-1992
		JP 8024594 B	13-03-1996
		JP 7028745 B	05-04-1995
		JP 62502895 T	19-11-1987
		KR 9009139 B1	22-12-1990
		LV 5289 A3	10-10-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/12607

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5453363 A		PT 83609 A ,B	01-11-1986
		SI 8611796 A ,B	31-10-1996
		SK 752686 A3	01-10-1996
		SU 1607689 A3	15-11-1990
		YU 179686 A1	30-06-1988
		ZA 8608012 A	24-06-1987
WO 9933988 A	08-07-1999	KR 253916 B1	01-05-2000
		AU 735480 B2	12-07-2001
		AU 1694199 A	19-07-1999
		BR 9814526 A	17-10-2000
		CA 2315750 A1	08-07-1999
		CN 1290299 T	04-04-2001
		EP 1042479 A1	11-10-2000
		JP 2002500013 T	08-01-2002
		WO 9933988 A1	08-07-1999
		US 5952461 A	14-09-1999